JP2023505221A - プログラム死リガンド１および／またはプログラム死リガンド２の調節物質 - Google Patents

プログラム死リガンド１および／またはプログラム死リガンド２の調節物質 Download PDF

Info

Publication number
JP2023505221A
JP2023505221A JP2022533441A JP2022533441A JP2023505221A JP 2023505221 A JP2023505221 A JP 2023505221A JP 2022533441 A JP2022533441 A JP 2022533441A JP 2022533441 A JP2022533441 A JP 2022533441A JP 2023505221 A JP2023505221 A JP 2023505221A
Authority
JP
Japan
Prior art keywords
compound
alkyl
cancer
hydrogen
pdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505221A5 (enExample
Inventor
マーク ジェイ スト
ビニ マシュー
レベッカ ブーヘイカー
Original Assignee
サウザーン リサーチ インスチチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サウザーン リサーチ インスチチュート filed Critical サウザーン リサーチ インスチチュート
Publication of JP2023505221A publication Critical patent/JP2023505221A/ja
Publication of JP2023505221A5 publication Critical patent/JP2023505221A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022533441A 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質 Pending JP2023505221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943728P 2019-12-04 2019-12-04
US62/943,728 2019-12-04
PCT/US2020/063137 WO2021113528A1 (en) 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

Publications (2)

Publication Number Publication Date
JP2023505221A true JP2023505221A (ja) 2023-02-08
JP2023505221A5 JP2023505221A5 (enExample) 2023-11-29

Family

ID=76222302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533441A Pending JP2023505221A (ja) 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質

Country Status (6)

Country Link
US (1) US12098216B2 (enExample)
EP (1) EP4069270A4 (enExample)
JP (1) JP2023505221A (enExample)
AU (1) AU2020396100A1 (enExample)
CA (1) CA3159698A1 (enExample)
WO (1) WO2021113528A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007060A2 (en) * 2005-07-07 2007-01-18 Zealand Pharma A/S N- or c- terminally modified small peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
WO2019084455A1 (en) 2017-10-26 2019-05-02 Southern Research Institute DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007060A2 (en) * 2005-07-07 2007-01-18 Zealand Pharma A/S N- or c- terminally modified small peptides

Also Published As

Publication number Publication date
US12098216B2 (en) 2024-09-24
CA3159698A1 (en) 2021-06-10
WO2021113528A1 (en) 2021-06-10
EP4069270A1 (en) 2022-10-12
EP4069270A4 (en) 2024-01-03
AU2020396100A1 (en) 2022-06-16
US20230029187A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
KR102725791B1 (ko) Cxcr2의 억제제
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
CN104822663B (zh) 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
US20180179179A1 (en) Heterocyclic compounds as immunomodulators
KR102810546B1 (ko) 암의 치료를 위한 4'-티오-뉴클레오타이드 및 -뉴클레오사이드 전구약물
TWI736578B (zh) 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
JP2020527577A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
WO2021022076A1 (en) Molecules and methods related to treatment of uncontrolled cellular proliferation
TW202028209A (zh) 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
EP4274559A1 (en) Modulators of programmed death-ligand-1
JP2023505221A (ja) プログラム死リガンド１および／またはプログラム死リガンド２の調節物質
EP4460294A2 (en) Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies
TW202017927A (zh) 作爲RET激酶抑制劑的取代的[1,2,4]三唑[1,5-a]吡啶化合物
US20220241310A1 (en) Thiarabine- and thiarabine prodrug-based treatments
WO2024192144A1 (en) Pyrazolopyrimidines as antidotes for arsenicals
JP2024540012A (ja) がん療法のための新規クロファラビン類似体の開発

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250717